Induction chemotherapy followed by allogeneic bone marrow transplantation or aggressive consolidation chemotherapy in childhood acute myeloblastic leukemia. A prospective study from the French Society of Pediatric Hematology and Immunology (SHIP).
In the LAME89/91 protocol, children with acute myeloid leukemia (AML) who achieved complete remission (CR) after induction chemotherapy, were treated either with allogeneic bone marrow transplantation (BMT) if they had an HLA-compatible related donor or with chemotherapy including high-dose cytarabine. The objectives of this study were to describe the overall results of this strategy and to compare the two post-remission arms. Two hundred and thirty-one children were enrolled in the protocol. Induction chemotherapy consisted of a combination of cytarabine and mitoxantrone. A CR was achieved in 204 children (88%).
Michel
G
G
Service d'Hématologie Pédiatrique, Hôpital d'Enfants la Timone, Marseille, France.
Baruchel
A
A
Tabone
M D
MD
Nelken
B
B
Leblanc
T
T
Thuret
I
I
Bordigoni
P
P
Bergeron
C
C
Esperou-Bourdeau
H
H
Perel
Y
Y
Vannier
J P
JP
De Lumley
L
L
Dommergues
J P
JP
Lamagnère
J P
JP
Couillaud
G
G
Auvrignon
A
A
Schaison
G
G
Leverger
G
G
D000208:Acute Disease; D016026:Bone Marrow Transplantation; D002648:Child; D002675:Child, Preschool; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D007223:Infant; D007951:Leukemia, Myeloid / Q000188:drug therapy / Q000628:therapy*; D008297:Male; D011379:Prognosis; D011446:Prospective Studies